Pharmaceutical Executive January 25, 2024
Sasser discusses how AI is directly helping with problems specific to precision and personalized medicine research.
Dr. Kate Sasser, chief scientific officer at Tempus, recently spoke with Pharmaceutical Executive about her work with AI. Tempus is focused on precision medicine, mainly in oncology but also other disease areas like cardiology and neurology. According to Sasser, AI is utilized across the entire precision medicine platform.
It’s used for unlocking different patient subgroups and understanding which medicines go best with those populations, developing next generation genomics test, trials, and other applications.
Pharmaceutical Executive: How is AI being used in the drug development process?
Kate Sasser: AI is really interesting in the drug development space. In the last few years,...
Today's Sponsors
Today's Sponsor